Literature DB >> 19811824

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.

Edgar Faber, Renata Mojzikova, Radek Plachy, Sarka Rozmanova, Marek Stastny, Martina Divoka, Marie Jarosova, Karel Indrak, Vladimir Divoky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19811824     DOI： 10.1016/j.leukres.2009.09.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.

Authors:  Simona Soverini; Antonella Vitale; Angela Poerio; Alessandra Gnani; Sabrina Colarossi; Ilaria Iacobucci; Giuseppe Cimino; Loredana Elia; Annalisa Lonetti; Marco Vignetti; Stefania Paolini; Giovanna Meloni; Valeria di Maio; Cristina Papayannidis; Marilina Amabile; Anna Guarini; Michele Baccarani; Giovanni Martinelli; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.

Authors:  Ahmet Emre Eşkazan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

Review 3.  Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review.

Authors:  E V Morozova; Y Y Vlasova; M V Pryanishnikova; K V Lepik; B V Afanasyev
Journal:  Biomark Insights       Date:  2015-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.